Signaling cascades as drug targets in model and pathogenic fungi

Current Opinion in Investigational Drugs

Volumn 9, Issue 8, 2008, Pages 856-864

  Bastidas, R J ^a   Reedy, J L ^a   Morales Johansson, H ^a   Heitman, J ^a   Cardenas, M E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Calcineurin; Cyclosporin A; FK 506; Geldanamycin; Hsp90; Rapamycin; Tor

Indexed keywords

ACTIN; AMPHOTERICIN B; CALCINEURIN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; GELDANAMYCIN; GLUCAN SYNTHASE; L 685818; MICAFUNGIN; NYSTATIN; PYRROLE DERIVATIVE; RADICICOL; RAPAMYCIN; TACROLIMUS; TANESPIMYCIN; TARGET OF RAPAMYCIN KINASE;

ANTIFUNGAL ACTIVITY; CELL PROLIFERATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FUNGAL VIRULENCE; GENETIC TRANSCRIPTION; GROWTH REGULATION; HUMAN; NONHUMAN; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; STRESS;

ANTIFUNGAL AGENTS; CALCINEURIN; DRUG DELIVERY SYSTEMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MYCOSES; PROTEIN-SERINE-THREONINE KINASES; SACCHAROMYCES CEREVISIAE PROTEINS; SIGNAL TRANSDUCTION;

EID: 48349141125     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 253(5022):905-909. •• This study presents a genetic screen that identified for the first time Tor1 and Tor2 as the targets of rapamycin in Saccharomyces cerevisiae.
2. Alarcon CM, Heitman J, Cardenas ME: Protein kinase activity and identification of a toxic effector domain of the target of rapamycin Tor proteins in yeast. Mol Biol Cell (1999) 10(8):2531-2546.
3. Bosotti R, Isacchi A, Sonnhammer EL: FAT: A novel domain in PIK-related kinases. Trends Biochem Sci (2000) 25(5):225-227.
4. Perry J, Kleckner N: The ATRs, ATMs, and TORs are giant HEAT repeat proteins. Cell (2003) 112(2):151-155.
5. Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F: Point mutations in Tor confer Rheb-independent growth in fission yeast and nutrient-independent mammalian Tor signaling in mammalian cells. Proc Natl Acad Sci USA (2007) 104(9):3514-3519.
6. Chen J, Zheng XF, Brown EJ, Schreiber SL: Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA (1995) 92(11):4947-4951.
7. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN: Two TOR complexes, only one of which is rapamycin-sensitive, have distinct roles in cell growth control. Mol Cell (2002) 10(3):457-468. •• This study, together with references [8] to [11], shows the characterization of the rapamycin-sensitive TORC1 and the rapamycin-insensitive TORC2 in Saccharomyces cerevisiae (see references [1•] and [2] to [9]) and Schizosaccharomyces pombe (see references [10] to [11]).
8. Wedaman KP, Reinke A, Anderson S, Yates J 3rd, McCaffery JM, Powers T: Tor kinases are in distinct membrane-associated protein complexes in Saccharomyces cerevisiae. Mol Biol Cell (2003) 14(3):1204-1220.
9. Reinke A, Anderson S, McCaffery JM, Yates J 3rd, Aronova S, Chu S, Fairclough S, Iverson C, Wedaman KP, Powers T: TOR complex 1 includes a novel component, Tco89p (YPL180w), and co-operates with Ssd1p to maintain cellular integrity in Saccharomyces cerevisiae. J Biol Chem (2004) 279(15):14752-14762.
10. Hayashi T, Hatanaka M, Nagao K, Nakaseko Y, Kanoh J, Kokubu A, Ebe M, Yanagida M: Rapamycin sensitivity of the Schizosaccharomyces pombe tor2 mutant and organization of two highly phosphorylated TOR complexes by specific and common subunits. Genes Cells (2007) 12(12):1357-1370.
11. Matsuo T, Otsubo Y, Urano J, Tamanoi F, Yamamoto M: Loss of the Tor kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast. Mol Cell Biol (2007) 27(8):3154- 3164.
12. Wang H, Jiang Y: The Tap42-protein phosphatase type 2A catalytic subunit complex is required for cell cycle-dependent distribution of actin in yeast. Mol Cell Biol (2003) 23(9):3116-3125.
13. Araki T, Uesono Y, Oguchi T, Toh EA: LAS24/KOG1, a component of the Tor complex 1 (TORC1), is needed for resistance to local anesthetic tetracaine and normal distribution of actin cytoskeleton in yeast. Genes Genet Syst (2005) 80(5):325-343.
14. Aronova S, Wedaman K, Anderson S, Yates J 3rd, Powers T: Probing the membrane environment of the Tor kinases reveals functional interactions between TORC1, actin, and membrane trafficking in Saccharomyces cerevisiae. Mol Biol Cell (2007) 18(8):2779-2794.
15. De Virgilio C, Loewith R: Cell growth control: Little eukaryotes make big contributions. Oncogene (2006) 25(48):6392-6415.
16. Rohde JR, Bastidas R, Puria R, Cardenas ME: Nutritional control via Tor signaling in Saccharomyces cerevisiae. Curr Opin Microbiol (2008) 11(2):153-160.
17. Crespo JL, Powers T, Fowler B, Hall MN: The Tor-controlled transcription activators GLN3, RTG1, and RTG3 are regulated in response to intracellular levels of glutamine. Proc Natl Acad Sci USA (2002) 99(10):6784-6789.
18. Cardenas ME, Heitman J: FKBP12-rapamycin target Tor2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. EMBO J (1995) 14(23):5892-5907.
19. Dubouloz F, Deloche O, Wanke V, Cameroni E, De Virgilio C: The TOR and EGO protein complexes orchestrate microautophagy in yeast. Mol Cell (2005) 19(1):15-26.
20. Gao M, Kaiser CA: A conserved GTPase-containing complex is required for intracellular sorting of the general amino-acid permease in yeast. Nat Cell Biol (2006) 8(7):657-667.
21. Zurita-Martinez SA, Puria R, Pan X, Boeke JD, Cardenas ME: Efficient Tor signaling requires a functional class C vps protein complex in Saccharomyces cerevisiae. Genetics (2007) 176(4):2139- 2150.
22. + in Schizosaccharomyces pombe is sensitive to rapamycin. Genetics (2005) 169(2):539-550.
23. + regulate arginine uptake and metabolism in Schizosaccharomyces pombe. J Biol Chem (2004) 279(13):12706-12713.
24. Powers T, Walter P: Regulation of ribosome biogenesis by the rapamycin-sensitive Tor-signaling pathway in Saccharomyces cerevisiae. Mol Biol Cell (1999) 10(4):987-1000.
25. Beck T, Hall MN: The Tor signaling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature (1999) 402(6762):689-692.
26. Cardenas ME, Cutler NS, Lorenz MC, Di Como CJ, Heitman J: The Tor signaling cascade regulates gene expression in response to nutrients. Genes Dev (1999) 13(24):3271-3279.
27. Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL: Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci USA (1999) 96(26):14866-14870. •bull; In this research, and that presented in reference [26], genome-wide gene expression analysis was employed to reveal that the transcriptional profile induced by rapamycin closely resembles that induced by nutrient limitation. Results presented in references [25] and [28] demonstrated that Tor signaling regulates gene expression by controlling the nuclear translocation of the target transcription factors.
28. Bertram PG, Choi JH, Carvalho J, Ai W, Zeng C, Chan TF, Zheng XF: Tripartite regulation of Gln3p by Tor, Ure2p, and phosphatases. J Biol Chem (2000) 275(46):35727-35733.
29. Di Como CJ, Arndt KT: Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev (1996) 10(15):1904-1916.
30. Jiang Y, Broach JR: Tor proteins and protein phosphatase 2A reciprocally regulate Tap42 in controlling cell growth in yeast. EMBO J (1999) 18(10):2782-2792.
31. Yan G, Shen X, Jiang Y: Rapamycin activates Tap42-associated phosphatases by abrogating their association with Tor complex 1. EMBO J (2006) 25(15):3546-3555.
32. Cox KH, Kulkarni A, Tate JJ, Cooper TG: Gln3 phosphorylation and intracellular localization in nutrient limitation and starvation differ from those generated by rapamycin inhibition of Tor1/2 in Saccharomyces cerevisiae. J Biol Chem (2004) 279(11):10270-10278.
33. Puria R, Zurita-Martinez SA, Cardenas ME: Nuclear translocation of Gln3 in response to nutrient signals requires Golgi-to-endosome trafficking in Saccharomyces cerevisiae. Proc Natl Acad Sci USA (2008) 105(20):7194-7199.
34. Georis I, Tate JJ, Cooper TG, Dubois E: Tor pathway control of the nitrogen-responsive DAL5 gene bifurcates at the level of Gln3 and Gat1 regulation in Saccharomyces cerevisiae. J Biol Chem (2008) 283(14):8919-8929.
35. Cherkasova VA, Hinnebusch AG: Translational control by Tor and Tap42 through dephosphorylation of eIF2α kinase Gcn2. Genes Dev (2003) 17(7):859-872.
36. Rohde JR, Campbell S, Zurita-Martinez SA, Cutler NS, Ashe M, Cardenas ME: Tor controls transcriptional and translational programs via Sap-Sit4 protein phosphatase signaling effectors. Mol Cell Biol (2004) 24(19):8332-8341.
37. Warner JR, Vilardell J, Sohn JH: Economics of ribosome biosynthesis. Cold Spring Harb Symp Quant Biol (2001) 66:567-574.
38. Jorgensen P, Rupes I, Sharom JR, Schneper L, Broach JR, Tyers M: A dynamic transcriptional network communicates growth potential to ribosome synthesis and critical cell size. Genes Dev (2004) 18(20):2491-2505.
39. Urban J, Soulard A, Huber A, Lippman S, Mukhopadhyay D, Deloche O, Wanke V, Anrather D, Ammerer G, Riezman H, Broach JR et al: Sch9 is a major target of TORC1 in Saccharomyces cerevisiae. Mol Cell (2007) 26(5):663-674.
40. Swinnen E, Wanke V, Roosen J, Smets B, Dubouloz F, Pedruzzi I, Cameroni E, De Virgilio C, Winderickx J: Rim15 and the crossroads of nutrient signaling pathways in Saccharomyces cerevisiae. Cell Div (2006) 1:3.
41. Schmidt A, Bickle M, Beck T, Hall MN: The yeast phosphatidylinositol kinase homolog Tor2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell (1997) 88(4):531-542.
42. Kamada Y, Fujioka Y, Suzuki NN, Inagaki F, Wullschleger S, Loewith R, Hall MN, Ohsumi Y: Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol Cell Biol (2005) 25(16):7239-7248.
43. Audhya A, Loewith R, Parsons AB, Gao L, Tabuchi M, Zhou H, Boone C, Hall MN, Emr SD: Genome-wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton. EMBO J (2004) 23(19):3747-3757.
44. Fadri M, Daquinag A, Wang S, Xue T, Kunz J: The pleckstrin homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2. Mol Biol Cell (2005) 16(4):1883-1900.
45. Aronova S, Wedaman K, Aronov PA, Fontes K, Ramos K, Hammock BD, Powers T: Regulation of ceramide biosynthesis by TOR complex 2. Cell Metab (2008) 7(2):148-158.
46. Mulet JM, Martin DE, Loewith R, Hall MN: Mutual antagonism of target of rapamycin and calcineurin signaling. J Biol Chem (2006) 281(44):33000-33007.
47. Daquinag A, Fadri M, Jung SY, Qin J, Kunz J: The yeast PH domain proteins Slm1 and Slm2 are targets of sphingolipid signaling during the response to heat stress. Mol Cell Biol (2007) 27(2):633-650.
48. Bultynck G, Heath VL, Majeed AP, Galan JM, Haguenauer-Tsapis R, Cyert MS: Slm1 and Slm2 are novel substrates of the calcineurin phosphatase required for heat stress-induced endocytosis of the yeast uracil permease. Mol Cell Biol (2006) 26(12):4729-4745.
49. Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis (2002) 2(2):73-85.
50. Blankenship JR, Steinbach WJ, Perfect JR, Heitman J: Teaching old drugs new tricks: Re-incarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs (2003) 4(2):192-199.
51. Vakil R, Knilans K, Andes D, Kwon GS: Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. Pharm Res (2008): doi:10.1007/s11095-008-9588-1. • This is the first study showing the fungicidal synergistic effects of lipid-formulated rapamycin, amphotericin B and 5-flucytosine on Candida albicans viability.
52. Cruz MC, Cavallo LM, Gorlach JM, Cox G, Perfect JR, Cardenas ME, Heitman J: Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and Tor kinase homologs in Cryptococcus neoformans. Mol Cell Biol (1999) 19(6):4101-4112.
53. Cruz MC, Goldstein AL, Blankenship J, Del Poeta M, Perfect JR, McCusker JH, Bennani YL, Cardenas ME, Heitman J: Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of Tor. Antimicrob Agents Chemother (2001) 45(11):3162-3170.
54. Cutler NS, Pan X, Heitman J, Cardenas ME: The Tor signal transduction cascade controls cellular differentiation in response to nutrients. Mol Biol Cell (2001) 12(12):4103-4113. •• The results in this study, along with those presented in references [51•] and [52], demonstrate that sublethal concentrations of rapamycin block filamentous differentiation via conserved FKBP12 and Tor homologs in Saccharomyces cerevisiae and in the human fungal pathogens Candida albicans and Candida neoformans.
55. Martins LF, Montero-Lomeli M, Masuda CA, Fortes FS, Previato JO, Mendonca-Previato L: Lithium-mediated suppression of morphogenesis and growth in Candida albicans. FEMS Yeast Res (2008) 8(4):615-621.
56. Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR: Nonfilamentous C albicans mutants are avirulent. Cell (1997) 90(5):939-949.
57. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL: Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell (2003) 2(5):1053-1060.
58. Zheng X, Wang Y, Wang Y: Hgc1, a novel hypha-specific G1 cyclin-related protein regulates Candida albicans hyphal morphogenesis. EMBO J (2004) 23(8):1845-1856.
59. Biswas K, Morschhauser J: The Mep2p ammonium permease controls nitrogen starvation-induced filamentous growth in Candida albicans. Mol Microbiol (2005) 56(3):649-669.
60. Dabas N, Morschhäuser J: Control of ammonium permease expression and filamentous growth by the GATA transcription factors Gln3 and Gat1 in Candida albicans. Eukaryot Cell (2007) 6(5):875-888.
61. Liao WL, Ramón AM, Fonzi WA: GLN3 encodes a global regulator of nitrogen metabolism and virulence of C albicans. Fungal Genet Biol (2008) 45(4):514-526.
62. Lee CM, Nantel A, Jiang L, Whiteway M, Shen SH: The serine/threonine protein phosphatase SIT4 modulates yeast-to-hypha morphogenesis and virulence in Candida albicans. Mol Microbiol (2004) 51(3):691-709.
63. Borel JF: Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology (1976) 31(4):631-641.
64. Goto T, Kino T, Hatanaka H, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK-506: Historical perspectives. Transplant Proc (1991) 23(6):2713-2717.
65. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J: Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol (2007) 5(6):418-430. • An excellent review on calcineurin biology in Cryptococcus neoformans, Candida albicans and Aspergillus fumigatus, as well as on the potential use of calcineurin for antifungal therapy.
66. Hemenway CS, Heitman J: Calcineurin. Structure, function, and inhibition. Cell Biochem Biophys (1999) 30(1):115-151.
67. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR: The mechanism of action of cyclosporin A and FK-506. Clin Immunol Immunopathol (1996) 80(3 Pt 2):S40-S45.
68. Fruman DA, Klee CB, Bierer BE, Burakoff SJ: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK-506 and cyclosporin A. Proc Natl Acad Sci USA (1992) 89(9):3686-3690.
69. Clipstone NA, Fiorentino DF, Crabtree GR: Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. J Biol Chem (1994) 269(42):26431-26437.
70. Heitman J, Cardenas ME, Breuder T, Hemenway C, Muir RS, Lim E, Goetz L, Zhu D, Lorenz M, Dolinski K: Antifungal effects of cyclosporin and FK-506 are mediated via immunophilin-dependent calcineurin inhibition. Transplant Proc (1994) 26(5):2833-2834.
71. Cardenas ME, Muir RS, Breuder T, Heitman J: Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. EMBO J (1995) 14(12):2772-2783.
72. Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of immunosuppression by cyclosporin, FK-506, and rapamycin. Curr Opin Nephrol Hypertens (1995) 4(6):472-477.
73. Odom A, Del Poeta M, Perfect J, Heitman J: The immunosuppressant FK-506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother (1997) 41(1):156-161.
74. Cruz MC, Del Poeta M, Wang P, Wenger R, Zenke G, Quesniaux VF, Movva NR, Perfect JR, Cardenas ME, Heitman J: Immunosuppressive and nonimmunosuppressive cyclosporin analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 44(1):143-149.
75. Fox DS, Cruz MC, Sia RA, Ke H, Cox GM, Cardenas ME, Heitman J: Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK-506 in Cryptococcus neoformans. Mol Microbiol (2001) 39(4):835-849.
76. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, Cardenas ME, Perfect JR, McCusker JH, Heitman J: Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 21(4):546-559. •• This study features the mechanism by which the calcineurin inhibitors cyclosporin A and FK-506 are toxic for C albicans in combination with the ergosterol biosynthesis inhibitor fluconazole. In addition, this synergism was observed with all azole antifungals tested, even among azole-resistant strains and several pathogenic fungi. Non- immunosuppressive cyclosporin analogs were also found to exert synergistic fungicidal activities against C albicans.
77. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS: Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother (2003) 51(2):313-316.
78. Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR: In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother (2004) 48(5):1664-1669.
79. Steinbach WJ, Cramer RA Jr, Perfect BZ, Henn C, Nielsen K, Heitman J, Perfect JR: Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 51(8):2979-2981.
80. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J: Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J (1997) 16(10):2576-2589.
81. Bader T, Bodendorfer B, Schröppel K, Morschhäuser J: Calcineurin is essential for virulence in Candida albicans. Infect Immun (2003) 71(9):5344-5354.
82. Blankenship JR, Wormley FL, Boyce MK, Schell WA, Filler SG, Perfect JR, Heitman J: Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell (2003) 2(3):422-430.
83. Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J: Calcineurin A of Candida albicans: Involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol (2003) 48(4):959-976.
84. Blankenship JR, Heitman J: Calcineurin is required for Candida albicans to survive calcium stress in serum. Infect Immun (2005) 73(9):5767-5774.
85. Onyewu C, Afshari NA, Heitman J: Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother (2006) 50(11):3963-3965.
86. Bader T, Schröppel K, Bentink S, Agabian N, Köhler G, Morschhäuser J: Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain. Infect Immun (2006) 74(7):4366-4369.
87. Steinbach WJ, Cramer RA Jr, Perfect BZ, Asfaw YG, Sauer TC, Najvar LK, Kirkpatrick WR, Patterson TF, Benjamin DK Jr, Heitman J, Perfect JR: Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 5(7):1091- 1103.
88. Onyewu C, Blankenship JR, Del Poeta M, Heitman J: Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother (2003) 47(3):956-964.
89. Reedy JL, Husain S, Ison M, Pruett TL, Singh N, Heitman J: Immunotherapy with tacrolimus (FK-506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. Antimicrob Agents Chemother (2006) 50(4):1573-1577.
90. Onyewu C, Eads E, Schell WA, Perfect JR, Ullmann Y, Kaufman G, Horwitz BA, Berdicevsky I, Heitman J: Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. Antimicrob Agents Chemother (2007) 51(10):3743-3746.
91. Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM et al: Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother (2008) 52(2):735-738.
92. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, Moreillon P: Fluconazole plus cyclosporin: A fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother (2000) 44(11):2932-2938.
93. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D: Potent synergism of the combination of fluconazole and cyclosporin in Candida albicans. Antimicrob Agents Chemother (2000) 44(9):2373-2381. • This is the first report showing that the calcineurin inhibitor cyclosporin, in conjunction with the ergosterol biosynthesis inhibitor fluconazole, exhibits synergistic fungicidal activity against C albicans.
94. Uppuluri P, Nett J, Heitman J, Andes D: Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother (2008) 52(3):1127- 1132.
95. Onyewu C, Wormley FL Jr, Perfect JR, Heitman J: The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infect Immun (2004) 72(12):7330-7333.
96. Cowen LE, Lindquist S: Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science (2005) 309(5744):2185-2189. •• A prescient study revealing a novel role for the molecular chaperone Hsp90 in the fixation and evolution of drug-resistant traits among fungi.
97. Santos M, de Larrinoa IF: Functional characterization of the Candida albicans CRZ1 gene encoding a calcineurin-regulated transcription factor. Curr Genet (2005) 48(2):88-100.
98. Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S: Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell (2006) 5(12):2184-2188.
99. Karababa M, Valentino E, Pardini G, Coste AT, Bille J, Sanglard D: CRZ1, a target of the calcineurin pathway in Candida albicans. Mol Microbiol (2006) 59(5):1429-1451.
100. Pardini G, De Groot PW, Coste AT, Karababa M, Klis FM, de Koster CG, Sanglard D: The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a predicted transglycosidase domain affects cell wall organization and virulence of Candida albicans. J Biol Chem (2006) 281(52):40399-40411.
101. Cowen LE: The evolution of fungal drug resistance: Modulating the trajectory from genotype to phenotype. Nat Rev Microbiol (2008) 6(3):187-198.
102. Imai J, Yahara I: Role of Hsp90 in salt stress tolerance via stabilization and regulation of calcineurin. Mol Cell Biol (2000) 20(24):9262-9270.
103. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH: Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem (1999) 42(2):260-266.
104. FitzGerald GA, Patrono C: The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med (2001) 345(6):433-442.
105. Flower RJ: The development of COX2 inhibitors. Nat Rev Drug Discov (2003) 2(3):179-191.
106. Mitchell JA, Warner TD: COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal antiinflammatory drugs. Nat Rev Drug Discov (2006) 5(1):75-86.
107. Fox DS, Heitman J: Good fungi gone bad: The corruption of calcineurin. Bioessays (2002) 24(10):894-903.